# Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta

> **NCT05950802** · PHASE1 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 40 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **RADIATION:** TLI

## Key facts

- **NCT ID:** NCT05950802
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-14
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05950802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05950802, "Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05950802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*